JPRN-UMIN000034080已完成2 期
Randomized Controlled Phase 2 Clinical Trial of JPH203 in Patients With Advanced Biliary Tract Cancers. - JPH203-SBECD-P2
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 106
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patient with severe disorders and/or unstable complications except cancers evaluated by investigator. 2) Patient with infection required systemic therapy. 3) Patient with positive HIV-1 antibody or HBs antigen or HCV-RNA. 4) Patient with ECG abnormality 5) Patient with pleural fluids, pericardial effusions or ascites required drainage
研究者
相似试验
进行中（未招募）
1 期
A study before surgery evaluating Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer.ocally advanced HER2-positive breast cancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004391-35-ESPuma Biotechnology Inc.126
进行中（未招募）
1 期
A study before surgery evaluating Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer.ocally advanced HER2-positive breast cancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004391-35-PTPuma Biotechnology Inc.126
进行中（未招募）
1 期
A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer. - NSABP FB-7 STUDYocally advanced HER2-positive breast cancerMedDRA version: 16.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004391-35-ITPuma Biotechnology Inc.141
进行中（未招募）
1 期
A study to evaluate the switch from prednisone to dexamethasone in prostate cancer patients being treated with abirateroneEUCTR2021-000943-30-ESSOGUG (Spanish Genitourinary Oncologic Group)110
尚未招募
不适用
A short-term ketogenic diet combined with 24-hour fasting and chemoprotection for patients with acute myeloid leukaemiaacute myeloid leukemiaACTRN12620000850976epean Blue Mountains Local Health District134